Swipe om te navigeren naar een ander artikel
This study used an empirical approach to identify and validate the classification of patients with schizophrenia in “good,” “moderate,” or “poor” functioning groups based on the assessment of functional measures.
Using data from a study of schizophrenia outpatients, patients were classified into functional groups using cluster analysis based on the Heinrich–Carpenter Quality of Life Scale (QLS), the 36-item Short-Form Health Survey (SF-36) Mental Component Summary Score, and a productivity measure. A three-cluster solution was chosen. Concurrent, convergent, and discriminant validity were assessed. Criteria for classifying patient functioning as “good,” “moderate,” or “poor” were established using classification and regression tree analysis.
The three clusters consistently differentiated patients on the QLS, SF-36 Mental Component Summary Score, and productivity measure. The clusters also differed on other functional measures and were concordant with previous functional classifications. Concurrent, convergent, and discriminant validity were good. “Good” functioning was identified as a QLS total score ≥84.5; “moderate” and “poor” functioning were separated by a cutoff score of 15.5 on the QLS intrapsychic foundation domain. Sensitivity ranged from 86 to 93 % and specificity from 89 to 99 %.
The heterogeneity in functioning of schizophrenia patients can be classified reliably in an empirical manner using specific cutoff scores on commonly used functional measures.
McGurk, S. R., Lee, M. A., Jayathilake, K., & Meltzer, H. Y. (2004). Cognitive effects of olanzapine treatment in schizophrenia. Medscape General Medicine, 6, 27. PubMed
Cramer, J. A., & Spilker, B. (1998). Quality of life and pharmacoeconomics: An introduction. Philadelphia, PA: Lippincott-Raven Publishers.
Cramer, J., Rosenheck, R., Xu, W., Henderson, W., Thomas, J., & Charney, D. (2001). Department of Veterans Affairs Cooperative Study Group on Clozapine in refractory schizophrenia. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia Bulletin, 27, 227–234. PubMedCrossRef
Stahl, S. M., Malla, A., Newcomer, J. W., Potkin, S. G., Weiden, P. J., Harvey, P. D., et al. (2010). A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: A 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. Journal of Clinical Psychopharmacology, 30, 425–430. PubMedCrossRef
Detke, H.C., Weiden, P.J., Llorca, P.M., Choukour, M., Watson, S.B., Brunner, E., et al. (2011). Open label comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized study in outpatients with schizophrenia. Presented at the 13th International Congress on Schizophrenia Research, April 2011, Colorado Springs, Colorado, USA [Abstract] Schizophrenia Bulletin 37 (Supplement 1), 300.
Ware, J. E., Jr, Snow, K. K., Kosinski, M., & Gandek, B. (1993). SF-36 health survey manual and interpretation guide. Boston: The Health Institute, New England Medical Center.
Tunis, S. L., Croghan, T. W., Heilman, D. K., Johnstone, B. M., & Obenchain, R. L. (1999). Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Medical Care, 37, 678–691. PubMedCrossRef
Kind, P., Hardman, G., & Macran, S. (1999). UK Population Norms for EQ- 5D. Discussion paper 172. Centre for Health Economics, University of York, York, 1–98.
Prieto, L., Novick, D., Sacristán, J. A., Edgell, E. T., Alonso, J., & SOHO Study Group. (2003). A Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica Supplement, 416, 24–29. CrossRef
Kay, S. R., Opler, L. A., & Lindenmayer, J. P. (1989). The positive and negative syndrome scale (PANSS): Rationale and standardization. British Journal of Psychiatry, 155(Suppl. 7), 59–65.
Kay, S. R. (1991). Positive and negative syndromes in schizophrenia. Assessment and research. New York: Brunner/Mazel.
Breiman, L., Friedman, J. H., Olshen, R. A., & Stone, C. J. (1984). Classification and regression trees. Calif., USA: Wadsworth, Inc.
Ritsner, M.S., Arbitman, M., Lisker, A., & Ponizovsky, A.M. (2011). Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factors. Quality of Life Research Oct 2 [Epub ahead of print].
Llorca, P.M., Blanc, O., Samalin, L., Bosia, M., Cavallaro, R. & on behalf of the EGOFORS Initiative (2011). Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry Jun. 29 [Epub ahead of print].
- Empirically driven definitions of “good,” “moderate,” and “poor” levels of functioning in the treatment of schizophrenia
Josep Maria Haro
- Springer Netherlands